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Porcine cell and organ transplantation provides promise for maintaining normal physiological conditions in patients with end-stage organ
failure. The approach however poses serious risk of transmitting pig pathogens to humans. Among many potential pathogens, porcine endogenous
retroviruses (PERV) are of particular concern due to their ubiquitous nature in pigs and capability of infecting human cells. Major antigenic
determinants and receptor binding domains on PERV remain unclear until now. Two monoclonal antibodies (mAb), named 8E10 and 7C4 capable
of neutralizing PERV infection in HEK293 cells are isolated at an IC50 of 3.0 and 2.7 μg/ml, respectively, in this work. Epitope location for mAb
8E10 was mapped to amino acids 427–434, residing at the C-terminal region of the gp70 component of type A PERV Env protein. The mAb 8E10
bound directly to the PERV indicating that the epitope is exposed on the virion surface. The mAb 7C4 epitope was assigned to the region
comprising amino acids 517–537 on the p15E component of PERV. In contrast to mAb 8E10, the 7C4 mAb bound native PERV inefficiently
suggesting that its epitope is accessible only after the virus interacts with its receptor. Finally, both mAbs variable regions were cloned and
nucleotide sequence determined. All together, these results reveal that both mAbs 8E10 and 7C4 effectively neutralize PERV infection and may be
used as a mean to prevent PERV infection in patients receiving xenotransplantation.
© 2006 Elsevier Inc. All rights reserved.Keywords: Envelope protein; Epitope mapping; Neutralizing antibody; Porcine endogenous retrovirusIntroduction
Pigs are the most likely donor organ source for various
reasons, including organ size, matching physiology, matters of
husbandry and ethical objections to using primates, to overcome
the severe human organ transplantation shortage. Besides acute
rejection, infection associated with pig pathogens is another
major concern in using porcine tissues for transplantation.
Among many potential pig-associated pathogens, porcine endo-
genous retroviruses (PERV) attract much attention due to their
ubiquitous nature in pigs, and capability in infecting human cells
(Le Tissier et al., 1997; Lower et al., 1996). Approximately 50
copies of PERV integration are reportedly present in the genome
of various pig breeds, and at least three subtypes (A, B and C) of⁎ Corresponding author. Fax: +886 3 5742910.
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doi:10.1016/j.virol.2006.11.016PERV are known to exist (Akiyoshi et al., 1998; Patience et al.,
2001; Takeuchi et al., 1998). Several lines of evidence have
shown that the risk of pig-to-human PERV transmission in
patients treated with pig cells is low (Blusch et al., 2000;
Kuddus et al., 2002; Switzer et al., 1999), although long term
PERV infection effects in humans remains to be investigated.
Closely related to PERVs are other mammalian type-C
retroviruses such as the gibbon ape leukemia virus, murine
leukemia virus (MuLV), feline leukemia virus (FeLV), and
baboon endogenous retrovirus (Akiyoshi et al., 1998; Le Tissier
et al., 1997). The PERV genes coding for capsid protein (gag)
and reverse transcriptase (pol) show particularly high homology
(50–60%) with other C-type retroviruses, whereas the envelope
protein (Env) gene is found less conserved among the group.
The Env protein is located on the virion surface and is the major
retrovirus antigenic determinant (Le Tissier et al., 1997;
Takeuchi et al., 1998). The protein is also responsible for
Fig. 1. Schematic representation of the domain organization of PERV Env
protein. The abbreviations are: RBD, receptor binding domain; PPR,
hypervariable proline-rich region; CR, C-terminal region of gp70; M,
membrane-spanning region; CT, cytoplasmic tail; R, R-peptide. The numbers
indicate the amino acid position of the start and end of each domain in type A
PERV Env protein derived from a ST-IOWA pig strain.
Fig. 2. Determination of the neutralization activity for the anti-Env mAb. An
unrelated mAb (anti-EBV-LMP-1, CT3.3) and a polyclonal antibody of PERV
Env were used as a negative and a positive control, respectively. The
neutralization activity of the antibodies at different concentrations is expressed
as percent of inhibition of the infection of HEK293 cells with approximately
3×103 infectious PERV particles as determined by immunofluorescence assays.
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events including receptor binding, conformational changes, and
membrane fusion between virus and host cells.
Retroviral Env proteins are trimers of heterodimers consist-
ing of one gp70 and one p15E molecule (Kobe et al., 1999).
Both gp70 and p15E derive from intracellular proteolytic
processing of the Env precursor protein (Pinter et al., 1997). The
N-terminal domain of gp70 is responsible for binding the virus
to cell surface receptor (Akiyoshi et al., 1998; Le Tissier et al.,
1997). The middle protein part is the variable proline-rich
region assigned the role of modulating conformation (Lavillette
et al., 1998). The conserved gp70 C-terminal region is also
required for viral entry (Gemeniano et al., 2006) and disulfide
bonded to p15E, anchored on the viral membrane through
several transmembrane domains. Finally, R-peptide, an 18-
residue region in the C-terminal cytoplasmic tail of p15E
modulates viral particle fusogenicity upon binding to the cell
surface receptor (Bobkova et al., 2002; Ragheb and Anderson,
1994; Rein et al., 1994). The gp70 component undergoes major
conformational rearrangements following receptor binding,
allowing the p15E protein to become active and trigger viral
and cytoplasmic lipid bilayer fusion. The domain organization
of PERV Env protein is depicted in Fig. 1.
Previous PERV research effort has been exerted on studying
detection methods, epidemiology, and viral infection outcomes
(Clemenceau et al., 1999; Martin et al., 1998). Few studies
concerning antigenic determinants and cell entry mechanism of
the virus have been reported (Fiebig et al., 2003; Gemeniano et
al., 2006; Langhammer et al., 2005; Watanabe et al., 2005). This
report describes epitope mapping of two neutralizing mono-
clonal antibodies (mAbs) specific to PERV Env protein. The
mAb binding activity to the virions and mAbs variable region
sequences are also reported herein. Information availability
from this study could facilitate future vaccine and immuno-
supplement development against PERV infection.
Results
Generation of mAb specific to PERV Env protein and
determination of their neutralization activity
A recombinant protein containing the region from amino
acid positions 332 to 615 (Env332–615) of the Env protein of type
A PERV (GenBank accession number AF296168), derived
originally from the ST-IOWA pig strain, was used as the miceimmunization antigen. Several reasons explain using the C-
terminal half of PERV Env protein as the antigen. First, this
region is more evolutionally conserved than the N-terminal half
and hence has a higher chance to obtain mAbs that could
recognize different PERV serotypes. Second, the C-terminal
region is demonstrably essential for PERV binding to the
receptor (Watanabe et al., 2005). Third, neutralizing antibodies
have been successfully generated in a related FeLV using Env
protein C-terminal region as the antigen (Langhammer et al.,
2005). Approximately 30 mAbs reacting positively with
Env332–615 were obtained using standard hybridoma techniques.
These mAbs were further tested for their neutralization activity
on PERV infection. Two mAbs, designated 8E10 and 7C4,
displayed a dose-dependent inhibition curve of PERV infection
in HEK293 cells as demonstrated in Fig. 2. In contrast, mAb
CT3.3, specific to the Epstein–Barr virus latent membrane
protein 1 (LMP1) (Fang et al., 2004), did not show any
neutralizing activity against PERV infection. The concentration
of 8E10 and 7C4 mAb required to achieve 50% inhibition
(IC50) of PERV infection was 3 and 2.7 μg/ml, respectively. As
mAb neutralization activities were considered relatively weak,
this work further examined whether 7C4 and 8E10 mAb activity
is specific to PERV by investigating mAb effect on infectivity
of a recombinant MuLV harboring the gfp reporter gene.
Results indicated that neither mAb exhibited significant
neutralization on the recombinant MuLV as determined by the
flow cytometer assay, reflecting 7C4 and 8E10 mAb high
specificity to PERV (Fig. 2).
Epitope mapping of the anti-Env mAb 8E10 and 7C4
The epitope recognized by 8E10 mAb was mapped using a
series of thioredoxin-fused Env protein fragments in either
immunoblotting assays or ELISA (Fig. 3). Besides that of the ST-
Fig. 3. Epitope mapping of 8E10 and 7C4 mAb. (A) Relative locations of full length and truncated recombinant Env proteins are shown. Protein fragments derived
from PERV type B are indicated in dotted lines and amino acid position numbers are adjusted to match corresponding PERV-A regions. (B) The recombinant proteins
synthesized in E. coli were analyzed by SDS-PAGE, stained with Coomassie Brilliant Blue R-250 (top panel) and subjected to Western blotting analysis with 8E10
(middle panel) and 7C4 (bottom panel). The bacterial lysates were: lanes 1, Env332–381; 2, Env375–441; 3, Env436–481; 4, Env460–561; 5, Env517–615; 6, Env332–416; 7,
Env397–481; 8, Env363–434 of PK–B; 9, Env363–426 of PK-B; 10, Env517–561; 11, Env460–539; 12, Env538–615; 13, Env513–557 of PK-B. The same set of recombinant
proteins were also used in ELISA (C). Samples 14–16 in the ELISA were lysates of E. coli NovaBlue, E. coli NovaBlue [pET32a], and purified Env332–615,
respectively.
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also utilized to determine mAb specificity. The origin of these
Env proteins include: PK-A, derived from a type A PERV of
PK15 (GenBank accession number AJ293656); PK-B, derived
from a typeB PERVof PK15 (AJ293657); PBMC-C, from a type-
C PERVof pig peripheral blood mononuclear cells (AF038600).
The relative position of these fragments on the Env protein are
shown in Fig. 3A, and their electrophoretic profile and Western
blotting analysis results as detected using mAb 8E10 and 7C4 are
shown in Fig. 3B. A similar study using the same set of
recombinant proteins in an ELISA was also performed and the
result is shown in Fig. 3C. Our results indicated that the mAb8E10 could recognize the PERV Env332–615 protein and its two
truncated derivatives comprising the region from amino acid 382
to 434 (Fig. 3B). On the other hand, the mAbwas unable to detect
any recombinant Env protein extending from amino acid 417 to
the C-terminus. By combining these data, the epitope site
recognized by 8E10 mAb could be mapped to amino acid
positions 417–434 of the PERV Env protein. Besides the Env
proteins of PERV type A strains, 8E10 mAb could detect the
recombinant PK-B Env fragment corresponding to the region
from amino acid 363 to 434 in PK-AEnv, whereas themAb failed
to recognize a PK-BEnv fragment comprising amino acids 363 to
426 (Figs. 3C and D). Multiple sequence alignment of the region
Fig. 5. Competition analysis of the interaction between the two mAb and their
epitopes. The recombinant Env proteins used as a competitor are shown in the
figure. BSA and Env1–331 were included as a negative and a positive control,
respectively.
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revealed three mismatches clustered at positions 417, 420, and
421 (Fig. 4). This finding further located the most likely epitope
position for this mAb to the region of amino acids 422 to 434 in
PERV-A Env.
A similar approach found that mAb 7C4 could detect all re-
combinant type A Env proteins containing the region from amino
acid 517 to 539 on the p15Emolecule. ThemAbdid not reactwith
the PK-B Env protein fragment corresponding to the region from
amino acid 513 to 557 of type A PERV Env protein (Fig. 4). The
result strongly suggested that 7C4 mAb is specific to PERV-A.
Verification of the mAb binding sites by competition ELISA
A competition ELISA using Env332–615 as the immobilized
antigen was performed to further verify epitopes mapped by
Western blotting and ELISA. All recombinant proteins contain-
ing the region 417–434, including Env332–615, Env397–481, and
PK-B Env363–434 could effectively block 8E10 mAb binding to
the antigen coated on plates (Fig. 5A). The IC50 of these proteins
in the ELISA was approximately 1 μg/ml. A synthetic peptide,
consisting of sequence YPEKAVLDEYDYRYNRPK, corre-
sponding to the region 417–434 of PERV-A Env (Fig. 4), could
also block interaction between 8E10 mAb and Env332–615 with
an IC50 at approximately 4.5 μg/ml. None of BSA, Env1–331, nor
PK-B Env363–434 exhibited any assay competition effect (Fig.
5A). Together, the results indicated that the amino acid sequence
of Env427–434 could be recognized specifically by 8E10 mAb.
A similar experiment was performed to verify the 7C4 mAb
binding site. Both Env332–615 and Env460–539 recombinant
proteins exhibited strong inhibition activity for 7C4 mAb
binding to the immobilized antigen Env332–615 (Fig. 5B). On the
other hand, PK-B Env540–584 did not show any inhibition as also
found when BSA was used as a competitor. Concentration of
these proteins required to achieve 50% reaction inhibition was
approximately 2 μg/ml.
Binding of the mAbs to PERV
A virus capture assay was performed to determine whether
these mAbs neutralized PERV infection through direct bindingFig. 4. Comparison of the sequences around the epitopic sites of the two mAb among
for 8E10 and 7C4 mAb. The predicted glycosylation sites of the Env proteins are mto the virions. The assay is based on detecting viral genomic
RNA presence by RT-PCR amplification of the region from
nucleotide 886 to 1007 of the viral gag gene (GenBankdifferent PERV Env proteins. The underlined sequences are the epitopes of Env
arked with bold-type letters.
Fig. 6. PERV–mAb binding assay. The culture medium of PK15 cells was
immunoprecipitated with 8E10 mAb, 7C4 mAb, anti-Env polyclonal antibody,
and an anti-LMP-1 mAb, CT3.3. The precipitates were analyzed by RT-PCR for
the presence of PERV genomic RNA (top panel) and regular PCR for the
contamination of cellular genomic DNA using β-actin as the target (bottom
panel).
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intact virions by these anti-Env mAb. Fig. 6 shows that the 8E10
mAb precipitated intact virions at a similar level as in the
polyclonal antibody raised with Env332–615. In contrast, mAb
7C4 as well as an unrelated mAb specific to EBV LMP1 could
not pull down PERV particles. These results clearly demon-
strated that 8E10, but not 7C4 mAb, exerted neutralization
activity through direct binding to the Env protein on the virions.
Sequence analysis of the variable regions of the mAb
The coding regions of the VL and VH domain of the 7C4 and
8E10 mAb were obtained individually by PCR amplification
using the cDNA prepared from the corresponding hybridomas.
The nucleotide sequence of the amplified DNA fragments was
determined and the predicted amino acid sequences were
aligned using IMGT/V-QUEST (http://imgt.cines.fr:8104/
textes/vquest). Our results showed that the VL and VH of
8E10 mAb contained 108 and 117 amino acid residues,
respectively. Similarly, 115 and 120 amino acid residues were
determined respectively for the two mAb 7C4 variable regions.
The VL gene of 8E10 was found a member of the κV3 family,
while 7C4 belongs to the κV1 family. A similar analysis showed
that the VH gene of 8E10 belonged to the H5 family whereas
that of 7C4 was most related to H1. The sequences of these VL
and VH genes have been deposited in the GenBank under the
accession number AAZ91686 and AAZ91687 (for 8E10 VL and
VH) and AAZ91688 and AAZ91689 (for 7C4 VL and VH),
respectively.
Discussion
Until now the precise mechanism concerning PERV Env
protein processing has not been defined clearly. Nevertheless,
because of the similarity in gene organization and sequence
between PERV and other C type retroviruses, it is conceivable
that their Env protein maturation process is also similar. The
cleavage site in Friend's MuLV, separating gp70 and p15E, is
within the basic amino acid sequence Arg/Lys-X-Lys-Arg at
amino acid position 480 (Akiyoshi et al., 1998; Le Tissier et al.,
1997), corresponding to amino acid 434/435 in Env protein oftype A PERV (Fig. 4). As the epitope for 8E10 mAb is mapped
to amino acids 427–434, and the mAb is capable of binding
directly to PERV, it is concluded that the C-terminal region of
gp70 is exposed on the PERV surface and is immunogenic. It
has been documented that the major receptor-binding site of the
related MuLV is located in the N-terminal half of gp70 (Fass
et al., 1997; Kobe et al., 1999; Lavillette and Kabat, 2004).
Therefore 8E10 mAb binding to its epitope will most likely
provide steric hindrance to interfere with intramolecular
interaction between the C-terminal region and the receptor-
binding site, an event required for subsequent membrane fusion
events (Burkhart et al., 2003). A recent report consistent with
findings of this study also shows that PERV-C infectivity and
host range is modulated by C-terminal region residues of its
envelope gp70 protein (Gemeniano et al., 2006).
This work demonstrates that the epitope for the 7C4 mAb
was mapped to a region extended out from the membrane-
spanning domain of the p15E component of PERV Env protein.
The epitope primarily displays a coil conformation, preceded by
a long α-helix. The p15E protein of retroviruses forms a dimeric
structure with gp70, responsible for direct binding to the host
cell receptor. Interaction between gp70 and receptor molecule
on the target cell surface could trigger dimeric structure
conformational change and expose the p15E, which in turn
activates fusion between cellular and viral membranes (Bur-
khart et al., 2003; Maerz et al., 2000; Wallin et al., 2004). Thus,
the mechanism of 7C4 mAb-mediated neutralization is more
likely due to blockage of p15E fusogenic activity after the virus
binds to the host cell receptor. The inability of the 7C4 mAb to
pull down the viral particle and a relatively high IC50 of the
mAb in the neutralization assay supports this notion.
Identifying PERV-neutralizing activity in 7C4 mAb is
consistent with a previous report in which goat antiserum
raised with recombinant p15E protein was capable of
neutralizing PERV infectivity (Fiebig et al., 2003). Mapping
the goat antibody epitopic site on p15E with overlapping
peptides revealed two major antigenic sites located distinctly
from the epitope of 7C4 mAb. The discrepancy may be in part
due to the use of different animals in antibody production. A
similar study identifying antigenic determinant on p15E
component of FeLV, a close relative of PERV, demonstrated
that antibody generated from different animals displayed a
somewhat different antigen recognition pattern (Langhammer
et al., 2005). Both rat and goat antibodies in the FeLV study
detected the two epitopes also found in their PERV study
(Fiebig et al., 2003). On the other hand, one neutralizing
epitope detected only by the goat antibody, but not the rat
antibody, is located in a region overlapped with the epitope
identified with the 7C4 mAb. These results strongly suggest
that the Env protein region from amino acid position 513 to
557, as detected by 7C4 mAb, is a neutralizing antigenic PERV
determinant.
The FeLV p15E protein affects lymphocyte differentiation
(Iwashiro et al., 2001) and CD4+ regulatory T cell expansion in
response to viral infection that can lead to immunosuppression.
A domain sequence LQNRRGLDILFLQEGGL is responsible
for FeLV immunosuppression effect (Langhammer et al., 2005).
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EGGL, is identified in PERV p15 that overlaps with the 7C4
mAb epitope. The two sequences are highly similar, therefore it
would not be surprising to find that PERV p15E also possesses
immunosuppressive activity. If this is the case, it will be very
interesting to see whether 7C4 mAb possesses activity to block
retrovirus-mediated immunosuppression.
Understanding how viral surface proteins interact with
neutralizing antibodies as well as the host receptor is essential
for vaccine and drug development to prevent viral infections.
Such studies normally rely on the availability of structure
information of both interacting proteins. A molecular structure
of a completely elucidated retroviral Env protein has not
existed to date that seriously hampers retrovirus infection
mechanism analysis. Membrane protein crystallization is
shown as often facilitated by forming complexes with specific
antibody fragments that stabilize individual domains and
interdomain interactions (Kwong et al., 1998). Thus, 8E10
and 7C4 mAb availability may provide useful tools for
crystallizing PERV gp70 and p15E and determining their
structures.
Very little information concerning the PERV infection
process has been available. The mAbs and the information
obtained through this work could potentially contribute to
PERV pathogenesis studies as well as many clinical
applications. A synthetic peptide corresponding to the epitope
of the 8E10 neutralizing antibodies for example, may be used
to block virus binding to its receptor thus preventing viral
infections. The epitope could induce neutralizing immunity,
making it a good candidate for peptide vaccine development.
Finally, the mAb could be humanized and engineered into
intrabodies and used as a therapeutic agent, which may be
particularly useful in preventing PERV infection in patients
receiving xenotransplantation.Materials and methods
Cell lines and viruses
Porcine kidney cell line, PK15 [ATCC CCL-33] and human
embryonic kidney HEK293 cells [ATCC CRL-1573] were
propagated in minimum essential medium (Sigma-Aldrich, St.
Louis, MO) supplemented with 5% calf serum and 10% horse
serum, respectively. The virus was precipitated from the growth
medium of PK15 or PERV-infected HEK293 cells by
centrifugation at 180,000×g for 60 min then resuspended in
NTE buffer (100 mM NaCl, 10 mM Tris, 1 mM EDTA, pH 8.0,
0.5% bovine serum albumin). Xenotropic MuLV (ATCC VR-
1447) was propagated on Mus dunni cells (ATCC CRL-2017)
for 14 days to allow the virus to spread completely. Virus
production was monitored by reverse transcriptase (RT) activity
and plaque forming assay on PG4(S+L−) cells as previously
described (Rigg et al., 1996). Approximately 1×104 pfu of the
purified MuLV were tested to determine their cross reactivity
with PERV Env mAb. Recombinant MuLV harboring a green
fluorescence protein (GFP) reporter gene was obtained fromHEK293 cells co-transfected with pLEGFP-c1 (Clontech, CA)
and pCL-Ampho (Imgenex, San Diego, CA) and the tittered
was determined on NIH3T3 cells.
Expression and purification of recombinant PERV Env protein
PERV gene fragments were obtained using PCR amplifica-
tion with either cDNA or genomic DNA of PK15 cells as the
template. The amplified fragments were cloned into either the
pET30a or pET32a expression vector (Novagen, San Diego,
CA) as indicated and clone correctness was verified by
nucleotide sequencing. Resulting plasmids were transformed
into Escherichia coli BL21(DE3) and hexahistidine-tagged
protein synthesis was induced with 0.5 mM isopropyl-D-
thiogalactopyranoside (IPTG). The IPTG-induced bacteria
were harvested by centrifugation at 8000×g, disrupted by
sonication, and the recombinant proteins were purified through
metal chelating affinity chromatography (Novagen). Eluted
protein purity was analyzed using sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE).
Western blotting analysis
Immunoblotting was used to characterize the mAb generated
in this study in relation to epitope location on PERV
recombinant proteins. Briefly, recombinant PERV proteins
were resolved by SDS-PAGE and transferred onto a poly-
vinylidene difluoride (PVDF) membrane (Millipore, Bedford,
MA). After blocking the membrane with 5% fat-free milk and
incubation with the testing mAb for 1 h at room temperature, a
1:5000 dilution of either horseradish peroxidase- or alkaline
phosphatase-conjugated secondary antibody (Jackson Immu-
noResearch, West Grove, PA) was added and the reaction was
continued for 1 h. After washing four times with PBS, the
membrane was incubated with peroxidase substrate SK-4800
(Vector Laboratories, Burlingame, CA) or alkaline phosphatase
substrates 5-bromo-4-chloro-3-indolyl-phosphate and nitroblue
tetrazolium for color development.
ELISA and competition binding assay
The recombinant Env proteins (20 ng/50 μl/well) were
immobilized overnight onto 96-well ELISA plates (Nalge
Nunc International, Rochester, NY) at 4 °C. The plates were
then blocked using 1% BSA in PBS for 1 h and washed four
times with PBS containing 0.05% Tween-20. The mAb was
added into the antigen coated plates and incubated for 1 h at
37 °C. The plate was washed thoroughly to remove unbound
mAb and incubated with a 1:5000 dilution of peroxidase-
conjugated goat anti-mouse IgG (Jackson ImmunoResearch)
for 1 h. Finally, peroxidase substrate 2,2′-azino-di(3-ethylen-
thiozoline sulfonate) (Kirkegaard and Perry Laboratories Inc.
Gaithersburg, MD) with H2O2 was added to the reaction and
incubated for approximately 15 min. The reaction was then
terminated by adding 1% SDS and the result was measured
spectrophotometrically at 405 nm. The competition ELISA
was performed as described previously (Anderson, 1984). The
370 C.-Y. Chiang et al. / Virology 361 (2007) 364–371peptides used in the competition assay were synthesized by
solid-phase method using FMOC-chemistry (GlycoNex,
Taiwan).
Virus neutralization assay
An assay involving a single round of virus infection
(Richman et al., 2003) was used to measure mAb neutraliza-
tion activity. Briefly, PERV preparations derived from PK15
cells were incubated with a serially 2-fold diluted testing mAb
for 1 h at 37 °C. An irrelevant mAb and BSA were also
included in the experiment as a negative control. The reaction
mixture was then inoculated onto HEK293 cells (∼6×103 cells/
well) on a 12-well dish, incubated for 1 h and the inoculum
was removed by washing the cells twice with PBS. Virus
infectivity was determined 72 h post-inoculation by immuno-
fluorescence analysis. Virus-incubated cells in the experiment
were fixed with ice-cold 4% paraformaldehyde (Merck,
Germany) for 30 min, blocked and washed as described
above for the ELISA. The fixed cells were incubated
sequentially with an appropriate dilution of the mAb A-11,
which specifically recognizes PERV Gag protein (Chiang
et al., 2005), and FITC-conjugated secondary antibody. The
infected cells were analyzed with either a fluorescence
microscope or a flow cytometer (FACSCalibur™, Becton,
Dickinson and Company, San Jose, CA). All experiments
were performed in triplicate and neutralization percentage was
calculated as [(N0−Nt) /N0]×100%, in which N0 is the
number of virus-infected cells without treatment and Nt
indicates the number of virus-infected cells with treatment.
Neutralizing activity was reported as the mAb concentration
required to confer 50% inhibition of the virus infection (IC50).
Neutralization activity of the mAb on GFP-carrying MuLV
was determined directly using flow cytometry.
PERV immunoprecipitation assay
The PERV preparation from PK15 cells was incubated with
100 μg anti-Env mAb in a volume of 1 ml for 1 h at room
temperature. Protein-A agarose beads were added to the mixture
to capture the virus–mAb complex at room temperature for 1 h.
After washing three times with 100 mM Tris–HCl, pH 8.0 and
once with 10 mM Tris–HCl pH 8.0, the RNA contained in the
immunoprecipitated complex was extracted using the TRI
Reagent (Molecular Research Center Inc., Cincinnati, OH). The
oligo(dT)-primed cDNAwas synthesized employing the Super-
Script Preamplification System (Invitrogen, Carlsbad, CA). The
cDNA was used as a template in the subsequent PCR for
detecting PERV presence.
Sequence determination of the variable region of the mAb
Total cellular RNA was extracted from the two mAb-
producing hybridomas and used in reverse transcription (RT)-
PCR to generate DNA fragments encoding antibody variable
regions. The degenerated oligonucleotides for variable region
PCR amplification were obtained from primer mixture ofMouse Scfv Module/Recombinant Phage Antibody Kit (Amer-
sham-Pharmacia Biosciences, NJ). The PCR amplified DNA
fragments were cloned into pGEM-T Easy vector (Promega,
Madison, WI), and their nucleotide sequence determined and
translated into protein sequence using the Vector NTI Suite VII
for analysis (Invitrogen, Carlsbad, CA).
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